Pfizer launches anti-diabetes drug

Pfizer Pakistan unveiled its Parke-Davis portfolio with a first-time entry into the anti-diabetes market with the launch of ‘Gliride’.
The foundation of Pfizer Parke-Davis is built on its promise to give the common Pakistani access to affordable treatments and therapies, with the highest quality standards that are a hallmark of Pfizer around the world.
Parke-Davis portfolio comprises of products offering treatments in cardiology, respiratory to antibiotics and others whilst plans are in place to address the most critical and prevalent ailments in Pakistan through this portfolio. Mr Abdul Majeed, Country Manager for Pfizer Pakistan,
Mr Abdul Majeed, Country Manager for Pfizer Pakistan, stated “Pakistan has a growing population with most of the people living in poor conditions. It is our shared responsibility to alleviate some of their health burden by providing high quality yet affordable treatment options. It is for this very reason that Pfizer Parke-Davis is offering a range of products in various therapeutic areas to take Pfizer’s mission of serving patients forward as we will continue to introduce more products under this portfolio.”
Gliride, which is an anti-diabetes drug, was launched amidst attendance by a large number of professionals and industry representatives. Prof. Dr. Zaman Shaikh (Head of Department, Endocrinology Department, Dow University of Health Sciences) addressed the participants on the occasion with his presentation on ‘prevalence of diabetes’.
Working in Pakistan for the last 50 years, Pfizer Pakistan has earned the reputation for marketing efficacious and reliable medicines. Its new Parke-Davis division offers high-quality and affordable medicines, within the reach of common man, for a wide range of areas, from cardiovascular and respiratory to anti-infective spheres.